ATE296839T1 - Antikörper zur krebsbehandlung und -diagnose - Google Patents

Antikörper zur krebsbehandlung und -diagnose

Info

Publication number
ATE296839T1
ATE296839T1 AT00912115T AT00912115T ATE296839T1 AT E296839 T1 ATE296839 T1 AT E296839T1 AT 00912115 T AT00912115 T AT 00912115T AT 00912115 T AT00912115 T AT 00912115T AT E296839 T1 ATE296839 T1 AT E296839T1
Authority
AT
Austria
Prior art keywords
antibodies
application
diagnosis
daf
directed against
Prior art date
Application number
AT00912115T
Other languages
English (en)
Inventor
Paul J Carter
John B Ridgway
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22401661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296839(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE296839T1 publication Critical patent/ATE296839T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00912115T 1999-03-01 2000-02-29 Antikörper zur krebsbehandlung und -diagnose ATE296839T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12226299P 1999-03-01 1999-03-01
PCT/US2000/005352 WO2000052054A2 (en) 1999-03-01 2000-02-29 Antibodies for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
ATE296839T1 true ATE296839T1 (de) 2005-06-15

Family

ID=22401661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912115T ATE296839T1 (de) 1999-03-01 2000-02-29 Antikörper zur krebsbehandlung und -diagnose

Country Status (11)

Country Link
US (2) US7288249B2 (de)
EP (1) EP1157041B1 (de)
JP (1) JP2002543044A (de)
AT (1) ATE296839T1 (de)
AU (1) AU770952B2 (de)
CA (1) CA2361877A1 (de)
DE (1) DE60020529T2 (de)
ES (1) ES2243240T3 (de)
IL (2) IL144559A0 (de)
PT (1) PT1157041E (de)
WO (1) WO2000052054A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
EP1157041B1 (de) 1999-03-01 2005-06-01 Genentech, Inc. Antikörper zur krebsbehandlung und -diagnose
SE0000597D0 (sv) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
CA2421751C (en) * 2000-09-11 2014-02-11 Donald W. Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7774144B2 (en) 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
NZ592340A (en) 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
EP1270732A1 (de) * 2001-06-21 2003-01-02 Schuler, Gerold Transfektion von eukaryotischen Zellen mit linearen Polynukleotiden mittels Elektroporation
IL160659A0 (en) * 2001-09-05 2004-08-31 Genentech Inc Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ES2288900T3 (es) * 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
WO2004013180A2 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
GB2392723B (en) * 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
GB0227644D0 (en) * 2002-11-27 2003-01-08 Cancer Rec Tech Ltd Specific binding members and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
AU2004293502B2 (en) * 2003-11-28 2010-12-02 National Research Council Of Canada Anticarcinoma antibodies and uses thereof
EP1749538A4 (de) * 2004-03-31 2009-11-11 Kirin Pharma Kk Verfahren zur auslösung der differenzierung von regulatorischen t-zellen und ihrer proliferation mit gpi-anker-protein-agonisten und medizinische zusammensetzung dafür
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
EP1623996A1 (de) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verbessertes Verfahren zur Auswahl eines Proteins von einer Bibliothek
WO2006049498A1 (en) * 2004-11-05 2006-05-11 Modiquest B.V. Means and methods for isolating and/or identifying a target molecule
US20050181479A1 (en) * 2005-03-04 2005-08-18 Medimmune, Inc. Periplasmic expression of antibodies using a single signal sequence
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
WO2007033167A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Compositions and methods for detecting and treating cancer
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2008156914A2 (en) 2007-05-30 2008-12-24 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
AU2013203265B2 (en) * 2007-08-29 2016-06-23 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
EP2088432A1 (de) * 2008-02-11 2009-08-12 MorphoSys AG Verfahren zur Identifikation eines Antikörpers oder eines Targets
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
ES2703714T3 (es) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
SG189950A1 (en) 2010-11-19 2013-06-28 Morphosys Ag A collection and methods for its use
EP2702411A4 (de) 2011-04-29 2015-07-22 Cancer Prevention & Cure Ltd Verfahren zur identifikation und diagnose von lungenkrankheiten mithilfe von klassifizierungssystemen und kits dafür
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
KR101875912B1 (ko) * 2016-10-13 2018-07-06 한국원자력연구원 암 표적 치료를 위한 방사성 동위원소가 표지된 cd55 표적 항체 및 이의 용도
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
US20220088193A1 (en) * 2019-02-20 2022-03-24 Agonox, Inc. Anti-CD55 Antibodies and Related Compositions and Methods
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS63500797A (ja) * 1985-05-24 1988-03-24 ニユ−ヨ−ク　ユニバ−シイテイ 崩壊加速因子に対するモノクロ−ン抗体、その生成方法および使用
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
ATE130764T1 (de) 1988-10-17 1995-12-15 Cancer Res Campaign Tech Anti-idiotyp antikörper induktion eines antitumorenresponses.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994026787A1 (en) 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
JP3562834B2 (ja) 1994-06-01 2004-09-08 孝夫 辻 便中ｄａｆ分子の検査方法
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US5985543A (en) 1996-10-11 1999-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods for detection of antibody binding to cells
AU6451998A (en) 1997-03-06 1998-09-22 Bard Diagnostic Sciences, Inc. Screening and treatment using complement regulator or receptor proteins
DK0979281T3 (da) * 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
GB9804065D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Tumour associated antigen 791Tgp72
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
EP1157041B1 (de) 1999-03-01 2005-06-01 Genentech, Inc. Antikörper zur krebsbehandlung und -diagnose
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
WO2007033167A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Compositions and methods for detecting and treating cancer

Also Published As

Publication number Publication date
WO2000052054A3 (en) 2001-08-23
EP1157041B1 (de) 2005-06-01
EP1157041A2 (de) 2001-11-28
JP2002543044A (ja) 2002-12-17
AU3389800A (en) 2000-09-21
DE60020529D1 (de) 2005-07-07
WO2000052054A2 (en) 2000-09-08
CA2361877A1 (en) 2000-09-08
AU770952B2 (en) 2004-03-11
PT1157041E (pt) 2005-10-31
US7288249B2 (en) 2007-10-30
US20080166698A1 (en) 2008-07-10
DE60020529T2 (de) 2006-04-27
IL144559A0 (en) 2002-05-23
IL144559A (en) 2006-12-10
US20030219434A1 (en) 2003-11-27
ES2243240T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ES8405071A1 (es) Un procedimiento de preparacion de conjugados inmunoenzimaticos.
MY121548A (en) Compounds and methods for the treatment of cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
EP0969720A4 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
EP0944389A4 (de) Gereinigte zubereitungen von 10-propargyl-10-deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
MXPA03007317A (es) Derivados de biotina y sus conjugados con agentes quelantes.
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2003040725A3 (en) Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1157041

Country of ref document: EP

RZN Patent revoked